Market Research Report
North America Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2030
|North America Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2030|
Published: June 21, 2022
Content info: 170 Pages
Delivery time: 2-3 business days
The North America Alzheimer's disease therapeutics & diagnostics market is predicted to increase with a 6.46% CAGR between the estimated years 2022 and 2030. Due to anticipated sales growth and the prospect of new therapies gaining market approval, the market is surging in the region.
The North America Alzheimer's disease therapeutics & diagnostics market growth evaluation entails the analysis of Canada and United States. According to the Alzheimer Society of Canada, thousands of new cases of dementia are diagnosed every year. By 2031, the number is expected to increase by 66%.
Since currently available drugs are unable to cure the disease, the benefits of these drugs gradually decrease with time. Further private and public insurers limit drug coverage for individuals who meet the insurance conditions. Therefore, the provincial government steps in and is responsible for Canada's healthcare facilities, which boosts the healthcare industry.
Moreover, advocacy groups like the Alzheimer's Society of Canada are also trying to improve drug coverage. Thus, owing to all the factors above, the Canadian market for Alzheimer's disease diagnostics and therapeutics is expected to register healthy growth over the forecast period.
Some of the leading companies in the market include: Eli Lilly & Company, Baxter International Inc, Johnson & Johnson, GE Healthcare, etc.